武田制药(TAK)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

TAK 武田制药

休市中 05-09 16:00:00 EDT

14.36

+0.09

+0.63%

盘后14.16

-0.20-1.38%

19:58 EDT

最高14.58	最低14.34	成交量435.35万
今开14.50	昨收14.27	日振幅1.65%
总市值453.25亿	流通市值433.83亿	总股本31.56亿
成交额6,282万	换手率0.14%	流通股本30.21亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"TAK","market":"US","secType":"STK","nameCN":"武田制药","latestPrice":14.36,"timestamp":1746820800000,"preClose":14.27,"halted":0,"volume":4353487,"hourTrading":{"tag":"盘后","latestPrice":14.1622,"preClose":14.36,"latestTime":"19:58 EDT","volume":1420,"amount":20366.3804,"timestamp":1746835130503},"delay":0,"floatShares":3021115373,"shares":3156322898,"eps":0.413946,"marketStatus":"休市中","change":0.09,"latestTime":"05-09 16:00:00 EDT","open":14.5,"high":14.575,"low":14.34,"amount":62822415.139729,"amplitude":0.016468,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.413946,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1747036800000},"marketStatusCode":7,"adr":0,"adrRate":0.5,"listingDate":1545627600000,"exchange":"NYSE","adjPreClose":14.27,"dividendRate":0.021588,"preHourTrading":{"tag":"盘前","latestPrice":14.53,"preClose":14.27,"latestTime":"09:23 EDT","volume":701218,"amount":10062586.98879,"timestamp":1746797029224},"postHourTrading":{"tag":"盘后","latestPrice":14.1622,"preClose":14.36,"latestTime":"19:58 EDT","volume":1420,"amount":20366.3804,"timestamp":1746835130503},"volumeRatio":2.1183934472332733,"impliedVol":0.3502,"impliedVolPercentile":0.588},"requestUrl":"/m/hq/s/TAK","defaultTab":"news","newsList":[{"id":"2534110437","title":"武田制药5月8日成交额为4458.56万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2534110437","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534110437?lang=zh_cn&edition=full","pubTime":"2025-05-09 10:58","pubTimestamp":1746759509,"startTime":"0","endTime":"0","summary":"美东时间2025年5月8日，武田制药成交额为4458.56万美元，成交额较昨日增加25.95%，当日成交量为310.74万股。武田制药于2025年5月8日跌5.25%，报14.27美元，该股过去5个交易日跌5.06%，年初至今涨10.44%，过去60日涨8.76%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-05-08|4458.56万|25.95%|310.74万|#|2025-05-07|3539.92万|0.94%|234.80万|#|2025-05-06|3506.82万|85.66%|229.87万|#|2025-05-05|1888.88万|-11.11%|122.88万|#|2025-05-02|2124.85万|-15.86%|138.70万|武田药品是日本最大的制药公司，2023财年的收入为4.3万亿日元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509105835a6d87bed&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509105835a6d87bed&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","TAK"],"gpt_icon":0},{"id":"2533713901","title":"武田制药盘中异动 早盘快速跳水5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2533713901","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533713901?lang=zh_cn&edition=full","pubTime":"2025-05-08 22:07","pubTimestamp":1746713262,"startTime":"0","endTime":"0","summary":"北京时间2025年05月08日22时07分，武田制药股票出现异动，股价大幅跳水5.01%。截至发稿，该股报14.31美元/股，成交量39.4699万股，换手率0.01%，振幅3.42%。机构评级方面，在所有16家参与评级的机构中，56%的券商给予买入建议，44%的券商给予持有建议，无券商给予卖出建议。武田制药股票所在的制药行业中，整体跌幅为2.50%。武田制药公司简介：武田药品是日本最大的制药公司，2023财年的收入为4.3万亿日元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508220742a476d94c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508220742a476d94c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","TAK"],"gpt_icon":0},{"id":"2533869910","title":"武田制药5月7日成交额为3539.92万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2533869910","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533869910?lang=zh_cn&edition=full","pubTime":"2025-05-08 10:49","pubTimestamp":1746672592,"startTime":"0","endTime":"0","summary":"美东时间2025年5月7日，武田制药成交额为3539.92万美元，成交额较昨日增加0.94%，当日成交量为234.80万股。武田制药于2025年5月7日跌0.73%，报15.06美元，该股过去5个交易日跌1.5%，年初至今涨16.56%，过去60日涨14.87%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-05-07|3539.92万|0.94%|234.80万|#|2025-05-06|3506.82万|85.66%|229.87万|#|2025-05-05|1888.88万|-11.11%|122.88万|#|2025-05-02|2124.85万|-15.86%|138.70万|#|2025-05-01|2525.49万|-8.47%|167.49万|武田药品是日本最大的制药公司，2023财年的收入为4.3万亿日元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508105002a6d70df5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508105002a6d70df5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","TAK"],"gpt_icon":0},{"id":"2533643239","title":"武田制药5月6日成交额为3506.82万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2533643239","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533643239?lang=zh_cn&edition=full","pubTime":"2025-05-07 10:49","pubTimestamp":1746586154,"startTime":"0","endTime":"0","summary":"美东时间2025年5月6日，武田制药成交额为3506.82万美元，成交额较昨日增加85.66%，当日成交量为229.87万股。武田制药于2025年5月6日跌1.37%，报15.17美元，该股过去5个交易日跌0.72%，年初至今涨17.41%，过去60日涨14.83%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-05-06|3506.82万|85.66%|229.87万|#|2025-05-05|1888.88万|-11.11%|122.88万|#|2025-05-02|2124.85万|-15.86%|138.70万|#|2025-05-01|2525.49万|-8.47%|167.49万|#|2025-04-30|2759.14万|62.69%|180.78万|武田药品是日本最大的制药公司，2023财年的收入为4.3万亿日元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507104918a6d5c357&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507104918a6d5c357&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","TAK"],"gpt_icon":0},{"id":"2533516282","title":"武田制药5月5日成交额为1888.88万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2533516282","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533516282?lang=zh_cn&edition=full","pubTime":"2025-05-06 10:45","pubTimestamp":1746499540,"startTime":"0","endTime":"0","summary":"美东时间2025年5月5日，武田制药成交额为1888.88万美元，成交额较昨日减少11.11%，当日成交量为122.88万股。武田制药于2025年5月5日涨0.39%，报15.38美元，该股过去5个交易日涨1.45%，年初至今涨19.03%，过去60日涨15.72%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-05-05|1888.88万|-11.11%|122.88万|#|2025-05-02|2124.85万|-15.86%|138.70万|#|2025-05-01|2525.49万|-8.47%|167.49万|#|2025-04-30|2759.14万|62.69%|180.78万|#|2025-04-29|1695.93万|-27.00%|111.14万|武田药品是日本最大的制药公司，2023财年的收入为4.3万亿日元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250506104541a6d47005&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250506104541a6d47005&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","TAK"],"gpt_icon":0},{"id":"2532807148","title":"武田制药5月2日成交额为2124.85万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2532807148","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532807148?lang=zh_cn&edition=full","pubTime":"2025-05-03 10:44","pubTimestamp":1746240295,"startTime":"0","endTime":"0","summary":"美东时间2025年5月2日，武田制药成交额为2124.85万美元，成交额较昨日减少15.86%，当日成交量为138.70万股。武田制药于2025年5月2日涨1.93%，报15.32美元，该股过去5个交易日涨1.93%，年初至今涨18.57%，过去60日涨17.39%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-05-02|2124.85万|-15.86%|138.70万|#|2025-05-01|2525.49万|-8.47%|167.49万|#|2025-04-30|2759.14万|62.69%|180.78万|#|2025-04-29|1695.93万|-27.00%|111.14万|#|2025-04-28|2323.05万|-29.22%|153.40万|武田药品是日本最大的制药公司，2023财年的收入为4.3万亿日元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250503104506a4708e43&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250503104506a4708e43&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TAK","BK4007"],"gpt_icon":0},{"id":"2532048724","title":"武田制药4月30日成交额为2759.14万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2532048724","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532048724?lang=zh_cn&edition=full","pubTime":"2025-05-01 10:45","pubTimestamp":1746067556,"startTime":"0","endTime":"0","summary":"美东时间2025年4月30日，武田制药成交额为2759.14万美元，成交额较昨日增加62.69%，当日成交量为180.78万股。武田制药于2025年4月30日涨0.07%，报15.29美元，该股过去5个交易日涨0.72%，年初至今涨18.34%，过去60日涨18.24%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-04-30|2759.14万|62.69%|180.78万|#|2025-04-29|1695.93万|-27.00%|111.14万|#|2025-04-28|2323.05万|-29.22%|153.40万|#|2025-04-25|3282.04万|-22.72%|218.82万|#|2025-04-24|4246.92万|74.71%|280.88万|武田药品是日本最大的制药公司，2023财年的收入为4.3万亿日元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250501104605a6cf960a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250501104605a6cf960a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","TAK"],"gpt_icon":0},{"id":"2531725141","title":"武田制药4月29日成交额为1695.93万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2531725141","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531725141?lang=zh_cn&edition=full","pubTime":"2025-04-30 10:43","pubTimestamp":1745981038,"startTime":"0","endTime":"0","summary":"美东时间2025年4月29日，武田制药成交额为1695.93万美元，成交额较昨日减少27.00%，当日成交量为111.14万股。武田制药于2025年4月29日涨0.79%，报15.28美元，该股过去5个交易日跌0.33%，年初至今涨18.26%，过去60日涨16.9%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-04-29|1695.93万|-27.00%|111.14万|#|2025-04-28|2323.05万|-29.22%|153.40万|#|2025-04-25|3282.04万|-22.72%|218.82万|#|2025-04-24|4246.92万|74.71%|280.88万|#|2025-04-23|2430.90万|-17.32%|159.71万|武田药品是日本最大的制药公司，2023财年的收入为4.3万亿日元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430104404a46d084f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430104404a46d084f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","TAK"],"gpt_icon":0},{"id":"2509264672","title":"日本制药股走高，中外制药涨超4%，盐野义制药涨超3%，武田制药、日本新药涨超1%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2509264672","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509264672?lang=zh_cn&edition=full","pubTime":"2025-02-06 08:57","pubTimestamp":1738803431,"startTime":"0","endTime":"0","summary":"日本制药股走高，中外制药涨超4%，盐野义制药涨超3%，武田制药、日本新药涨超1%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/06085747977826.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1574","BK1191","01477","BK4007","TAK"],"gpt_icon":0},{"id":"2507629998","title":"Julie Kim将于明年接替卫博科出任武田制药总裁兼CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2507629998","media":"港股那点事","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2507629998?lang=zh_cn&edition=full","pubTime":"2025-01-30 21:58","pubTimestamp":1738245480,"startTime":"0","endTime":"0","summary":"格隆汇1月30日｜武田制药宣布，董事会一致决定由公司美国业务部总裁Julie Kim接替卫博科（Christophe Weber）出任公司总裁、CEO兼代表董事，2026年6月生效，后者届时将退休。               \n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/bxjj/2025-01-30/doc-inehunpu2484439.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BRCD","BK4007","TAK"],"gpt_icon":0},{"id":"2507669648","title":"Takeda Pharmaceutical(TAK.US)：2024年Q3财报实现营收75.13亿美元，前值为78.85亿美元；每股收益为0.44美元，前值为0.51美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2507669648","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2507669648?lang=zh_cn&edition=full","pubTime":"2025-01-30 17:24","pubTimestamp":1738229099,"startTime":"0","endTime":"0","summary":"Takeda Pharmaceutical(TAK.US)：2024年Q3财报实现营收75.13亿美元，前值为78.85亿美元；每股收益为0.44美元，前值为0.51美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/30172447906893.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["TAK"],"gpt_icon":0},{"id":"1188918826","title":"武田药品提高2024财年指导预期：核心收入和利润预期小幅增长，核心每股收益调整为持平或略有下降，自由现金流提高至5500亿至6500亿日元","url":"https://stock-news.laohu8.com/highlight/detail?id=1188918826","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188918826?lang=zh_cn&edition=full","pubTime":"2025-01-30 15:30","pubTimestamp":1738222214,"startTime":"0","endTime":"0","summary":"武田药品更新了其2024财年的管理指导和报告及核心预测。这些调整主要受产品动能和运营费用节约的推动，同时也反映了修订后的全年汇率假设。根据最新的预测，核心收入预计将小幅增长，而核心每股收益预计与之前持平或略微下降。此外，自由现金流的预期被上调至5500亿至6500亿日元。查看更多详情，请参考《2024财年财务预测修订公告》。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TAK"],"gpt_icon":0},{"id":"1118495484","title":"武田药品2024年第三季度GAAP每股收益为15.01日元，同比下降67.38日元，销售额为1.144万亿日元，超出预期1.139万亿日元","url":"https://stock-news.laohu8.com/highlight/detail?id=1118495484","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118495484?lang=zh_cn&edition=full","pubTime":"2025-01-30 14:56","pubTimestamp":1738220174,"startTime":"0","endTime":"0","summary":"武田药品  报告季度每股收益为15.01日元。这较去年同期的每股收益67.38日元下降了77.72%。公司报告季度销售额为1.144万亿日元，超出分析师一致预期的1.139万亿日元，超出0.42%。以上内容来自Benzinga Earnings专栏，原文如下：Takeda Pharmaceutical  reported quarterly earnings of 15.01 per share. This is a 77.72 percent decrease over earnings of 67.38 per share from the same period last year. The company reported quarterly sales of 1.144 trillion which beat the analyst consensus estimate of 1.139 trillion by 0.42 percent. This is a 2.97 percent increase over sales of 1.111 trillion the same","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"武田药品2024年第三季度GAAP每股收益为15.01日元，同比下降67.38日元，销售额为1.144万亿日元，超出预期1.139万亿日元","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TAK"],"gpt_icon":0},{"id":"2492957434","title":"金十数据整理：每日美股市场要闻速递（12月17日 周二）","url":"https://stock-news.laohu8.com/highlight/detail?id=2492957434","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492957434?lang=zh_cn&edition=full","pubTime":"2024-12-17 21:47","pubTimestamp":1734443243,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["NVDS","QGmain","LU0683600562.USD","3NVD.UK","NFLX","NVD3.UK","UGAZ","2NVD.UK","TSLA","NVDS.UK","NVIW.SI","META","NVDL","TSLL","TSYW.SI","161631","LU2420271590.USD","LU0345770308.USD","PLTR","161027","MRK","NVDA","RTX","SNVD.UK","TAK","BK4547","BK4587","LU2468319806.SGD","DGAZ","NGmain","LU0861579265.USD","NVD","NVD2.UK","NVDY","BK4503","CVX","SG9999014898.SGD","IE00BMPRXR70.SGD","UNG","LU2054465674.USD","LU2505996681.GBP","NVDX","LU2097344431.USD","NVDU","HK0000306701.USD","IE00BMPRXN33.USD","NVDD"],"gpt_icon":0},{"id":"2492954105","title":"武田制药(TAK.US)CD38单抗在中国再获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2492954105","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492954105?lang=zh_cn&edition=full","pubTime":"2024-12-17 21:06","pubTimestamp":1734440793,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，12月16日，中国国家药监局药品审评中心网站最新公示，武田制药1类新药mezagitamab注射剂获得一项新的临床试验默示许可，拟开发治疗原发性免疫性血小板减少症。Mezagitamab治疗旨在提供快速且持续的血小板应答改善，并恢复血小板计数至功能水平。在中国，武田已经完成该产品治疗持续性/慢性原发性免疫性血小板减少症的2期临床研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1226207.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","TAK"],"gpt_icon":0},{"id":"2488304161","title":"武田制药(TAK.US)与Keros Therapeutics合作开发血液疾病创新疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2488304161","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488304161?lang=zh_cn&edition=full","pubTime":"2024-12-04 15:30","pubTimestamp":1733297410,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，Keros Therapeutics今天宣布与武田制药达成一项独家全球开发和商业化许可协议，以推进elritercept的开发。此外，3期临床试验RENEW将很快启动患者招募，研究elritercept在患有极低风险、低风险或中等风险MDS且依赖输血的成人患者中的疗效。自协议生效之日起，武田将负责elritercept的所有开发、生产和商业化工作。根据协议内容，Keros将收到2亿美元的预付款，并有资格获得超过11亿美元的开发、监管及商业里程碑付款。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1220172.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LENZ","BK4007","TAK","BK4139"],"gpt_icon":0},{"id":"2482485092","title":"武田制药2024财年第三财季实现净利润6.17亿美元，同比增加285.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2482485092","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482485092?lang=zh_cn&edition=full","pubTime":"2024-11-09 00:00","pubTimestamp":1731081624,"startTime":"0","endTime":"0","summary":"11月9日，武田制药公布财报，公告显示公司2024财年第三财季净利润为6.17亿美元，同比增加285.84%；其中营业收入为78.80亿美元，同比增加9.20%，每股基本收益为0.19美元。机构评级：截至2024年11月9日，当前有13家机构对武田制药目标价做出预测，其中目标均价为15.92美元，其中最低目标价为13.73美元，最高目标价为19.29美元。公司简介：武田药品工业是日本最大的制药公司，2023财年的收入为4.3万亿日元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241109000056a224f576&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241109000056a224f576&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TAK"],"gpt_icon":0},{"id":"2481925398","title":"武田制药在进博会重申承诺，推动幽门螺杆菌防控助力健康中国","url":"https://stock-news.laohu8.com/highlight/detail?id=2481925398","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481925398?lang=zh_cn&edition=full","pubTime":"2024-11-07 15:23","pubTimestamp":1730964180,"startTime":"0","endTime":"0","summary":"在第七届中国国际进口博览会上，武田制药举办了\"无幽家庭一小步、健康中国一大步\"专场主题发布会，介绍其在幽门螺杆菌治疗领域的布局和未来发展。活动汇聚了消化领域专家、医疗专业人士等，围绕幽门螺杆菌的认知、筛查和治疗展开交流，以提升公众对该感染的认识和防范意识，共同推动\"健康中国\"战略目标。武田制药在消化领域深耕多年，其创新药物富马酸伏诺拉生片已获批用于根除幽门螺杆菌，为患者提供新的治疗选择。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2024-11-07/doc-incvfpzf7693581.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["TAK","BK4007"],"gpt_icon":0},{"id":"2481289999","title":"武田(TAK.US)在中国启动两项3期临床试验  针对“过度睡眠”病症推出创新疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2481289999","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481289999?lang=zh_cn&edition=full","pubTime":"2024-11-07 15:18","pubTimestamp":1730963896,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中国药物临床试验登记与信息公示平台官网近日公示，武田(TAK.US)在中国启动了两项TAK-861的国际多中心3期临床研究，分别为一项评价TAK-861治疗发作性睡病伴猝倒的疗效和安全性的研究，以及一项在患有选定中枢性睡眠过度疾病的受试者中开展的评价TAK-861长期安全性和耐受性的研究。公开资料显示，TAK-861是一种口服食欲素受体2(OX2R)激动剂。该产品治疗发作性睡病1型(NT1)适应症此前已经被中国NMPA纳入突破性治疗品种，以及获美国FDA授予治疗NT1中过度白天过度嗜睡的突破性疗法认定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1207913.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1576","03347","BK1141","BK4007","TAK","BK1583"],"gpt_icon":0},{"id":"2481190223","title":"家无幽 我守护|武田举办幽门螺杆菌主题发布活动 助力健康中国","url":"https://stock-news.laohu8.com/highlight/detail?id=2481190223","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481190223?lang=zh_cn&edition=full","pubTime":"2024-11-07 14:56","pubTimestamp":1730962560,"startTime":"0","endTime":"0","summary":"儿童是幽门螺杆菌感染的高风险群体，主要由父母尤其是母亲传播。感染了幽门螺杆菌的家庭成员始终是潜在的传染源，具有持续传播的可能性。我国幽门螺杆菌感染整体基数大，以家庭为单位防控幽门螺杆菌感染是阻断感染和传播的重要策略，有助于夯实健康中国的基础。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4550472_ZH50472_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["TAK","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.takeda.com","stockEarnings":[{"period":"1week","weight":-0.0627},{"period":"1month","weight":0.0014},{"period":"3month","weight":0.0613},{"period":"6month","weight":0.0421},{"period":"1year","weight":0.074},{"period":"ytd","weight":0.0846}],"compareEarnings":[{"period":"1week","weight":-0.0043},{"period":"1month","weight":0.0287},{"period":"3month","weight":-0.0606},{"period":"6month","weight":-0.0566},{"period":"1year","weight":0.0849},{"period":"ytd","weight":-0.0371}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Takeda Pharmaceutical Company Limited是一家在日本注册成立的上市公司成立于1925年1月12日。该公司及其子公司是一家主要的全球制药集团，从事医药产品、非处方药和准药品消费品以及其他医疗保健产品的研究、开发、制造和营销。武田的主要医药产品包括以下治疗领域的药物：胃肠病学、肿瘤学和神经科学。","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":0.034112},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.007122},{"month":3,"riseRate":0.571429,"avgChangeRate":-0.002095},{"month":4,"riseRate":0.571429,"avgChangeRate":-0.002036},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.007955},{"month":6,"riseRate":0.166667,"avgChangeRate":-0.019551},{"month":7,"riseRate":0.5,"avgChangeRate":0.0124},{"month":8,"riseRate":0.666667,"avgChangeRate":0.001502},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.021841},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.059656},{"month":11,"riseRate":0.666667,"avgChangeRate":0.06202},{"month":12,"riseRate":0.666667,"avgChangeRate":0.008882}],"exchange":"NYSE","name":"武田制药","nameEN":"Takeda Pharmaceutical Co Ltd"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.4","shortVersion":"4.33.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"武田制药(TAK)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供武田制药(TAK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"武田制药,TAK,武田制药股票,武田制药股票老虎,武田制药股票老虎国际,武田制药行情,武田制药股票行情,武田制药股价,武田制药股市,武田制药股票价格,武田制药股票交易,武田制药股票购买,武田制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"武田制药(TAK)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供武田制药(TAK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}